Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + gemcitabine + nab-paclitaxel as first-line therapy for advanced pancreatic cancer
ChiCTR2300072843Phase 2Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in pancreatic cancer (PC), sponsored by Shenzhen Second People's Hospital. Primary endpoints: objective response rate and progression-free survival. Started Jun 2023; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300072843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072843.